Vifor Pharma released H1 17 results broadly in line with our estimates as well as market consensus. Reported revenue came in at CHF625.7m (+13.6%) on the back of sustained growth in the iron deficiency business (+9.1%; accounts for c.45% of H1 17 sales). Within the iron franchise, Ferinject/Injectafer was the primary growth contributor (+18.7%; accounts for c.31% of H1 17 sales) led by robust demand in the US. However, sales for the other intravenous/IV iron drug ‘Venofer’ fell 12
28 Aug 2017
Good start to the year; full-year guidance upgraded
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Good start to the year; full-year guidance upgraded
Galenica AG (0ROG:LON) | 0 0 0.0% | Mkt Cap: 2,446m
- Published:
28 Aug 2017 -
Author:
Sumit Sayal -
Pages:
4
Vifor Pharma released H1 17 results broadly in line with our estimates as well as market consensus. Reported revenue came in at CHF625.7m (+13.6%) on the back of sustained growth in the iron deficiency business (+9.1%; accounts for c.45% of H1 17 sales). Within the iron franchise, Ferinject/Injectafer was the primary growth contributor (+18.7%; accounts for c.31% of H1 17 sales) led by robust demand in the US. However, sales for the other intravenous/IV iron drug ‘Venofer’ fell 12